

Chronic Steatohepatitis (NASH)-North America Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/OBD173CE84FEN.html>

Date: December 2017

Pages: 150

Price: US\$ 3,480.00 (Single User License)

ID: OBD173CE84FEN

Abstracts

Report Summary

Chronic Steatohepatitis (NASH)-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Chronic Steatohepatitis (NASH) industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Chronic Steatohepatitis (NASH) 2013-2017, and development forecast 2018-2023

Main market players of Chronic Steatohepatitis (NASH) in North America, with company and product introduction, position in the Chronic Steatohepatitis (NASH) market
Market status and development trend of Chronic Steatohepatitis (NASH) by types and applications

Cost and profit status of Chronic Steatohepatitis (NASH), and marketing status

Market growth drivers and challenges

The report segments the North America Chronic Steatohepatitis (NASH) market as:

North America Chronic Steatohepatitis (NASH) Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

United States

Canada

Mexico

North America cholic Steatohepatitis (NASH) Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Weight Loss Treatment
Insulin-Sensitizing Agents
Lipid-Lowering Drugs
Antioxidants
Other Agents

North America cholic Steatohepatitis (NASH) Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital
Clinics
Drug Store
Research institute
Others

North America cholic Steatohepatitis (NASH) Market: Players Segment Analysis (Company and Product introduction, cholic Steatohepatitis (NASH) Sales Volume, Revenue, Price and Gross Margin):

Boehringer Ingelheim
Cerenis Therapeutics
Connexios Life Sciences
Genfit
Islet Sciences
Nimbus Therapeutics
Verva Pharmaceuticals
Viking Therapeutics
Astellera Plc
Galmed Pharmaceuticals Ltd.
GENFIT SA
Gilead Science
Novo Nordisk
Immuron Ltd
Intercepts Pharmaceuticals

Enzo Biochem, Inc
Tobira Therapeutics, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF OHOLIC STEATOHEPATITIS (NASH)

- 1.1 Definition of oholic Steatohepatitis (NASH) in This Report
- 1.2 Commercial Types of oholic Steatohepatitis (NASH)
 - 1.2.1 Weight Loss Treatment
 - 1.2.2 Insulin-Sensitizing Agents
 - 1.2.3 Lipid-Lowering Drugs
 - 1.2.4 Antioxidants
 - 1.2.5 Other Agents
- 1.3 Downstream Application of oholic Steatohepatitis (NASH)
 - 1.3.1 Hospital
 - 1.3.2 Clinics
 - 1.3.3 Drug Store
 - 1.3.4 Research institute
 - 1.3.5 Others
- 1.4 Development History of oholic Steatohepatitis (NASH)
- 1.5 Market Status and Trend of oholic Steatohepatitis (NASH) 2013-2023
 - 1.5.1 North America oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023
 - 1.5.2 Regional oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of oholic Steatohepatitis (NASH) in North America 2013-2017
- 2.2 Consumption Market of oholic Steatohepatitis (NASH) in North America by Regions
 - 2.2.1 Consumption Volume of oholic Steatohepatitis (NASH) in North America by Regions
 - 2.2.2 Revenue of oholic Steatohepatitis (NASH) in North America by Regions
- 2.3 Market Analysis of oholic Steatohepatitis (NASH) in North America by Regions
 - 2.3.1 Market Analysis of oholic Steatohepatitis (NASH) in United States 2013-2017
 - 2.3.2 Market Analysis of oholic Steatohepatitis (NASH) in Canada 2013-2017
 - 2.3.3 Market Analysis of oholic Steatohepatitis (NASH) in Mexico 2013-2017
- 2.4 Market Development Forecast of oholic Steatohepatitis (NASH) in North America 2018-2023
 - 2.4.1 Market Development Forecast of oholic Steatohepatitis (NASH) in North America 2018-2023
 - 2.4.2 Market Development Forecast of oholic Steatohepatitis (NASH) by Regions

2018-2023

CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole North America Market Status by Types

3.1.1 Consumption Volume of oholic Steatohepatitis (NASH) in North America by Types

3.1.2 Revenue of oholic Steatohepatitis (NASH) in North America by Types

3.2 North America Market Status by Types in Major Countries

3.2.1 Market Status by Types in United States

3.2.2 Market Status by Types in Canada

3.2.3 Market Status by Types in Mexico

3.3 Market Forecast of oholic Steatohepatitis (NASH) in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of oholic Steatohepatitis (NASH) in North America by Downstream Industry

4.2 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Major Countries

4.2.1 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in United States

4.2.2 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Canada

4.2.3 Demand Volume of oholic Steatohepatitis (NASH) by Downstream Industry in Mexico

4.3 Market Forecast of oholic Steatohepatitis (NASH) in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

5.1 North America Economy Situation and Trend Overview

5.2 oholic Steatohepatitis (NASH) Downstream Industry Situation and Trend Overview

CHAPTER 6 OHOLIC STEATOHEPATITIS (NASH) MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

- 6.1 Sales Volume of oholic Steatohepatitis (NASH) in North America by Major Players
- 6.2 Revenue of oholic Steatohepatitis (NASH) in North America by Major Players
- 6.3 Basic Information of oholic Steatohepatitis (NASH) by Major Players
 - 6.3.1 Headquarters Location and Established Time of oholic Steatohepatitis (NASH) Major Players
 - 6.3.2 Employees and Revenue Level of oholic Steatohepatitis (NASH) Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 OHOLIC STEATOHEPATITIS (NASH) MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Boehringer Ingelheim
 - 7.1.1 Company profile
 - 7.1.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.1.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
- 7.2 Cerenis Therapeutics
 - 7.2.1 Company profile
 - 7.2.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.2.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Cerenis Therapeutics
- 7.3 Connexios Life Sciences
 - 7.3.1 Company profile
 - 7.3.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.3.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Connexios Life Sciences
- 7.4 Genfit
 - 7.4.1 Company profile
 - 7.4.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.4.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Genfit
- 7.5 Islet Sciences
 - 7.5.1 Company profile
 - 7.5.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.5.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Islet Sciences
- 7.6 Nimbus Therapeutics

- 7.6.1 Company profile
- 7.6.2 Representative oholic Steatohepatitis (NASH) Product
- 7.6.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Nimbus Therapeutics
- 7.7 Verva Pharmaceuticals
 - 7.7.1 Company profile
 - 7.7.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.7.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Verva Pharmaceuticals
- 7.8 Viking Therapeutics
 - 7.8.1 Company profile
 - 7.8.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.8.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Viking Therapeutics
- 7.9 Astazeneca Plc
 - 7.9.1 Company profile
 - 7.9.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.9.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Astazeneca Plc
- 7.10 Galmed Pharmaceuticals Ltd.
 - 7.10.1 Company profile
 - 7.10.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.10.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Galmed Pharmaceuticals Ltd.
- 7.11 GENFIT SA
 - 7.11.1 Company profile
 - 7.11.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.11.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of GENFIT SA
- 7.12 Gilead Science
 - 7.12.1 Company profile
 - 7.12.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.12.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Gilead Science
- 7.13 Novo Nordisk
 - 7.13.1 Company profile
 - 7.13.2 Representative oholic Steatohepatitis (NASH) Product
 - 7.13.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Novo Nordisk

7.14 Immuron Ltd

7.14.1 Company profile

7.14.2 Representative oholic Steatohepatitis (NASH) Product

7.14.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Immuron Ltd

7.15 Intercepts Pharmaceuticals

7.15.1 Company profile

7.15.2 Representative oholic Steatohepatitis (NASH) Product

7.15.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Intercepts Pharmaceuticals

7.16 Enzo Biochem, Inc

7.17 Tobira Therapeutics, Inc.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

8.1 Industry Chain of oholic Steatohepatitis (NASH)

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

9.1 Cost Structure Analysis of oholic Steatohepatitis (NASH)

9.2 Raw Materials Cost Analysis of oholic Steatohepatitis (NASH)

9.3 Labor Cost Analysis of oholic Steatohepatitis (NASH)

9.4 Manufacturing Expenses Analysis of oholic Steatohepatitis (NASH)

CHAPTER 10 MARKETING STATUS ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: oholic Steatohepatitis (NASH)-North America Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/OBD173CE84FEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OBD173CE84FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970